Defining the role for the gut microbiome in the clinical efficacy of sulfasalazine therapy for IBD associated spondyloarthritis

• DOI: 10.4049/jimmunol.204.supp.237.8
• Publication Date: 2023-01-01T14:28:20Z
• Authors: Svetlana Ferreira...; Randy Longman; Amanda Rupert; Monica Viladomiu; Andrew Marderstein; Gregory Putzel; Gabriela Funez-de...; Viola Woo; Maeva L Metz; Ellen J Scherl; Lance Chou
• Keywords: Faecalibacterium prausnitzii; Sulfasalazine

Abstract Spondyloarthritis (SpA) is the most common extra-intestinal manifestation of inflammatory bowel disease (IBD). Sulfasalazine (SAS) one earliest medications used in IBD and its efficacy spondyloarthritis thought to depend on antibacterial properties. Therefore, our study aims diagnostically evaluate role for fecal microbiome clinical response SAS identify microbial immunologic therapeutic targets associated with response. We have longitudinally followed IBD-SpA patients subjected therapy. Clinical data, including validated joint activity scores, samples from 19 were collected at baseline week 2 12 after initiation. Metagenomic sequencing was define effect relationship symptoms improvement. Gnotobiotic mouse models test sufficiency observed patients. Fecal SAS-responders distinct that non-responders 6 pre-treatment markers (including Faecalibacterium prausnitzii) predicted SAS-response (AUC: 0.9). SPF mice germ-free colonized patient microbiota revealed selectively reduced mucosal-associated bacteria. a critical A. muciniphila modulating mucosal inflammation. Our reveals ability target bacteria modulate impact pathobionts. This highlights potential use microbial-based diagnostic tools improve drug strategies IBD-SpA.